Tilray

pharmaceutical and cannabis company

TLRY Nasdaq ISIN US88688T1007 SEC CIK 1731348 LEI 549300Y4V60733TO1478
Follow Tilray Weekly email: filings, results

Financials

Reported figures only · latest: Q1 2027 USD · US GAAP
Revenue, last quarter $257.1M +22.7% vs same quarter last year
Net income −$43.1M −13297.8% vs same quarter last year
EPS, diluted −$0.32
Operating cash flow −$16.5M −1133.5% vs same quarter last year
Revenue by quarter
$211M
$185.8M
$224.5M
$209.5M
$217.5M
$206.7M
$281.7M
$257.1M
Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$3B−$2B−$1B$0$1BFY17FY18FY20FY22FY23FY24FY25FY26
Show the numbers
YearRevenueNet income
FY26$915.5M−$121.4M
FY25$821.3M−$2.2B
FY24$788.9M−$245M
FY23$627.1M−$1.5B
FY22$628.4M−$476.8M
FY20$405.3M−$102.5M
FY18$20.5M−$7.8M
FY17$12.6M−$7.9M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300%−200%−100%0%100%FY17FY18FY20FY22FY23FY24FY25FY26
Show the numbers
YearGross marginOperating marginNet margin
FY2628.4%−6.9%−13.3%
FY2529.3%−277.9%−266.3%
FY2428.3%−22.1%−31.1%
FY2323.4%−218.4%−231.6%
FY2218.6%−97.1%−75.9%
FY2023.7%−25.7%−25.3%
FY1855.4%−36.5%−38%
FY1721.1%−55.7%−62.3%
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY17FY18FY20FY22FY23FY24FY25FY26
Show the numbers
YearFree cash flow
FY26-
FY25−$127.5M
FY24−$60.2M
FY23−$12.9M
FY22−$211.3M
FY20−$174.4M
FY18−$16.9M
FY17−$3.8M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Tilray
  • Healthcare median
−300%−200%−100%0%FY17FY18FY20FY22FY23FY24FY25FY26
Show the numbers
YearTilrayHealthcare median
FY26−13.3%−11.1%
FY25−266.3%−30.6%
FY24−31.1%−47%
FY23−231.6%−58%
FY22−75.9%−80.4%
FY20−25.3%−62.2%
FY18−38%−49.6%
FY17−62.3%−45.9%